Introduction
Paroxysmal nocturnal haemoglobinuria, haemolytic anaemia and aplastic anaemia are three different disorders that share many clinical and laboratory features.
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder that happens when part of your immune system attacks and damages your red blood cells and platelets. If left untreated, PNH can cause haemolytic anaemia, chronic kidney disease, or thrombosis (blood clots).1 “Paroxysmal” means sudden, “nocturnal” means night, and “haemoglobinuria” refers to urine stained with blood. With PNH, the urine is dark because your immune system breaks down your own red blood cells, a process known as haemolysis.
Haemolytic anaemia (HA) occurs when your red blood cells deplete or die before your body can replace them with new blood cells. People can get haemolytic anaemia if they inherit anaemia-causing genetic disorders, certain illnesses, or drugs.2
Aplastic anaemia (AA) is when damaged bone marrow can’t make enough new blood cells and platelets. Leaving the condition untreated can become life-threatening.3
All of these conditions may present with anaemia, fatigue, and laboratory signs of haemolysis or cytopenia. Clinicians use a systematic approach to distinguish between them. Hence, this article will run over the pathophysiology, diagnostic framework, including clinical presentation and laboratory findings, and also management of the three different disorders.
Overview of the conditions
Individuals with PNH have some haematopoietic stem cells that are poorly functioning, producing defective blood cells. These defective red blood cells are highly susceptible to early death, as they are targeted by a particular part of the immune system called the complement system. The destruction of red blood cells (haemolysis) by complement leads to haemoglobin in the urine (haemoglobinuria).1
PNH is due to a genetic mutation in hematopoietic stem cells. The mutation of the X-linked gene phosphatidylinositol glycan class A (PIGA) produces a deficiency in the glycosylphosphatidylinositol (GPI) protein, which is responsible for anchoring other proteins to the surface of red blood cells.
The lack of the GPI protein means that the proteins responsible for regulating the complement system cannot attach to PNH-affected red blood cells. This disrupts complement inhibition, leading to chronic haemolysis of PHN-affected cells. This has secondary complications, mainly through intravascular haemolysis, thrombosis and bone marrow failure.
Haemolytic anaemia is a class of anaemia that is caused by the destruction of red blood cells, increased haemoglobin catabolism (breakdown of haemoglobin), and decreased levels of haemoglobin. It can be inherited, something that you're born with, or acquired, something you develop after birth.
When a red blood cell is unable to change shape as it passes through the spleen, it is isolated and removed by phagocytosis. Antibodies can also cause drug-induced haemolysis, infections, or direct trauma. Destruction can also occur due to inherited protein deficits, fragmentation, increased oxidative stress or decreased energy production.
Aplastic anaemia is marked by bone marrow failure, followed by pancytopenia. This condition must be promptly recognised, as the untreated condition carries a high mortality rate. Aplastic anaemia develops due to immune-mediated and intrinsic mechanisms, as well as genetic and environmental factors. This multifactorial basis of the condition emphasises the importance of a targeted therapeutic approach for each individual. But the most common reason is that the immune system attacks blood stem cells in the bone marrow, which fail to produce enough new blood cells (red cells, white cells, and platelets).3
Shared clinical features and overlap
Although PNH, haemolytic anaemia (HA), and aplastic anaemia (AA) are distinct entities, patients often present with overlapping symptoms that complicate diagnosis. Fatigue, being pale, and reduced exercise tolerance are common to all three. Dyspnoea (shortness of breath) on exertion and general malaise ( feeling of discomfort) are also often reported. Moreover, many haemolytic features overlap, including the following:
- Both PNH and other forms of HA can present with jaundice, elevated lactate dehydrogenase (LDH), and reduced haptoglobin. Dark-coloured urine, a hallmark of intravascular haemolysis, may appear in PNH and in certain severe haemolytic states, further blurring the fine lines between the two disorders during diagnosis
- PNH can either coexist with or evolve from AA, meaning individuals may display pancytopenia (a reduction of all three types of blood cells) alongside haemolysis. Similarly, individuals with AA often present with profound fatigue and bleeding symptoms, which may mimic the cytopenias of advanced PNH. Hence, there is an overlap of bone marrow dysfunction
Because these shared features are relevant to each condition, a specialist relying solely on symptoms or basic blood tests can lead to misclassification. It is therefore essential for specialists to pay careful attention to the smallest detail and use a combination of diagnostic tools to distinguish between conditions.5,6
Distinguishing features: Clinical presentation
The distinguishing features of the clinical presentation of the three conditions are listed below.4,5
PNH
- Classic triad, which includes haemolysis, thrombosis, and bone marrow failure. These features have been listed below:
- Haemoglobinuria (often nocturnal, dark urine in the morning)
- Unusual thrombosis sites (hepatic, cerebral veins)
- Dysphagia, abdominal pain due to smooth muscle dystonia (nitric oxide scavenging)9
Haemolytic anemia
- Jaundice, splenomegaly and gallstones
- Acute vs. chronic features depend on the cause
- Usually lacks the thrombosis and urine findings seen in PNH
Aplastic anaemia
- Bleeding (petechiae, bruising) from thrombocytopenia
- Recurrent infections from neutropenia
- Typically, absence of signs of haemolysis (no dark urine, minimal jaundice)
Distinguishing features: Laboratory findings
Although there are many overlaps among the three conditions, a few distinct key laboratory findings can help healthcare professionals make a more accurate diagnosis.8
- Flow cytometry is the gold standard for diagnosing PNH. Flow cytometry shows the percentage of red and white PNH cells in your blood. It is more accurate for measuring white blood cells during, or just after, an episode of haemolysis or a blood transfusion. Hence, this will show the absence of CD55 and CD59
- Lactate dehydrogenase (LDH) is tested frequently in PNH individuals. It gives an idea of the extent of haemolysis in the body. PNH individuals experiencing haemolysis will have high LDH and elevated levels of bilirubin. In addition, a urinalysis can detect haemoglobinuria and haemosiderinuria
- As mentioned, pancytopenia can occur with bone marrow failure, which can be detected on bone marrow examination
- In haemolytic anaemia, laboratory tests reveal the consequences of sped up red cell destruction and the overuse of bone marrow stem cells. A higher reticulocyte count is typical, reflecting increased erythropoiesis, while elevated LDH and indirect bilirubin, together with low haptoglobin, signal active hemolysis. You may also find free plasma haemoglobin or haemoglobinuria in the veins. The direct antiglobulin (Coombs) test can identify and confirm acquired immune-mediated haemolysis when positive
- Blood smears provide further diagnostic clues, such as spherocytes in inherited haemolytic anaemia, schistocytes (in small blood vessel involvement), or sickled cells (in haemoglobinopathies). Unlike aplastic anaemia, bone marrow in haemolytic states is usually hypercellular, underlying the difference between bone marrow destruction and failure of production. Laboratory tests are central to distinguishing haemolytic anaemia from PNH and AA, despite overlapping biochemical markers
- Finally, with AA, pancytopenia with hypocellular bone marrow (fewer cells in the bone marrow) can also be viewed via bone marrow examination, yet the shape of red blood cells remains normal (tested via a blood smear). Furthermore, a complete blood count can be done to assess reticulocyte count (which is low) and haemolysis markers such as elevated LDH and indirect bilirubin
Management implications
Symptoms are managed differently across these conditions, emphasising the importance of accurate diagnosis. For PNH, treatment focuses on complement inhibitors (i.e., eculizumab and ravulizumab), which block complement-mediated haemolysis. Patients with thrombosis may require anticoagulation (blood thinning), and in severe or stubborn cases, haematopoietic stem cell transplantation can be considered.7
For haemolytic anaemia, therapy focuses heavily on the underlying cause. Options range from corticosteroids and rituximab in immune-mediated cases to splenectomy or long-term transfusion support in more severe cases. Immunosuppressants may also be indicated for specific subtypes.
In AA, the primary treatment is immunosuppressive therapy, most commonly anti-thymocyte globulin (ATG) in combination with cyclosporine. ATG targets T cells, which drive marrow suppression, while cyclosporine provides longer-term modulation of the immune system. Supportive measures such as red cell and platelet transfusions, infection-prevention medications, and, in suitable cases, stem cell transplantation, are also vital.
FAQs
Why is it important to differentiate between paroxysmal nocturnal anaemia, haemolytic anaemia and aplastic anaemia?
Though very similar in terms of a few general signs and symptoms, the prognosis and treatment are very different. Hence, diagnosis must be accurate for effective treatment.
What is the triad of paroxysmal nocturnal haemoglobinuria?
The triad of paroxysmal nocturnal haemoglobinuria includes:
- Haemolytic anaemia
- Bone marrow failure
- Propensity to thromboembolism
What are the main causes of haemolytic anaemia?
These include sickle cell disease and thalassemia.
Is aplastic anaemia curable?
At the moment, there’s no cure. However, stem cell therapy may be the first possible cure for aplastic anaemia.
Summary
Despite sharing clinical and laboratory features and treatment, there are a few signs and symptoms that can be useful in differentiating paroxysmal nocturnal hemoglobinuria from haemolytic anaemia and aplastic anaemia, too. PNH is primarily managed with complement inhibitors such as eculizumab or ravulizumab, alongside anticoagulation for thrombosis, with stem cell transplantation reserved for severe cases.
Hemolytic anaemia therapies depend on the cause, ranging from corticosteroids and rituximab in autoimmune forms to splenectomy or transfusion support in severe disease. Finally, in aplastic anaemia, immunosuppressive therapy with anti-thymocyte globulin and cyclosporine forms the cornerstone, often combined with transfusions, infection-prevention measures, or stem cell transplantation. These contrasts emphasise how accurately differentiating between the three conditions directly guides effective treatment and improves individual prognosis.
References
- Shah N, Bhatt H. Paroxysmal Nocturnal Hemoglobinuria. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Nov 27]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK562292/.
- Baldwin C, Pandey J, Olarewaju O. Hemolytic Anemia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Nov 27]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK558904/.
- Nimmana BK, Penney SW. Aplastic Anemia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Nov 27]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK534212/.
- Hill QA, Stamps R, Massey E, Grainger JD, Provan D, Hill A, et al. The diagnosis and management of primary autoimmune haemolytic anaemia. Br J Haematol [Internet]. 2017 [cited 2025 Nov 27]; 176(3):395–411. Available from: https://onlinelibrary.wiley.com/doi/10.1111/bjh.14478.
- Oliver M, Patriquin CJ. Paroxysmal Nocturnal Hemoglobinuria: Current Management, Unmet Needs, and Recommendations. J Blood Med [Internet]. 2023 [cited 2025 Nov 27]; 14:613–28. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10710797/.
- Gavriilaki E, Tragiannidis A, Papathanasiou M, Besikli S, Karvouni P, Douka V, et al. Aplastic anemia and paroxysmal nocturnal hemoglobinuria in children and adults in two centers of Northern Greece. Front Oncol [Internet]. 2022 [cited 2025 Nov 27]; 12:947410. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684709/.
- Shakir A, Narula S, LaGrow A, Nusrat S. Two Roads Diverge: Treatment Choice in Coexisting Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. J Med Cases [Internet]. 2020 [cited 2025 Nov 27]; 11(6):182–4. Available from: http://www.journalmc.org/index.php/JMC/article/view/3478.
- Waheed A, Shammo J, Dingli D. Paroxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape. Blood Reviews [Internet]. 2024 [cited 2025 Nov 27]; 64:101158. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0268960X23001285.
- Liu C, Liu X, Janes J, Stapley R, Patel RP, Gladwin MT, et al. Mechanism of faster NO scavenging by older stored red blood cells. Redox Biology [Internet]. 2014 [cited 2025 Nov 27]; 2:211–9. Available from: https://linkinghub.elsevier.com/retrieve/pii/S221323171300102X.

